2023-06-16 21:43:00
A vaccine once morest to chikungunya produced an immune response in 98.9% of volunteers. This information comes from a study published in the scientific journal The Lancet regarding the vaccine developed by the French biotechnology company Valneva. The results are similar to those of the preliminary tests, carried out in 2021.
In total, recruited 4.115 healthy adults, with the dose of the compound called VLA1553 being applied in 3.082 of these people. Martina Schneider is clinical strategy manager at Valneva, lead author of the research and spoke in a press release regarding the novelty:
This might be the first chikungunya vaccine available to people living in endemic regions, as well as travelers to endemic areas or areas at risk for a future outbreak.
Generally speaking, this vaccine works around a modified version of the live chikungunya virus, which can multiply in the body without causing illness. In this sense, the intent is to mimic natural infections and trigger a robust immune response that provides broader protection.
According to what the study pointed out, VLA1553 was well tolerated even among older volunteers. For those who don’t know, the immunizer’s way of acting is similar to that of the triple viral, as well as smallpox and yellow fever. Schneider also addressed the age issue:
As age is a risk factor for the severity and mortality of chikungunya disease, the strong immune response seen in older participants may be particularly beneficial.
1686977695
#Chikungunya #virus #vaccine #achieves #immune #response